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platform for increased stability and homogeneity†
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Samad Hossain,‡abd Ravinder Goyal,‡a Manoj Pandey,‡a Jwala Sivaccumar,‡a
Sazid Hussain,‡a Arindam Sarkar,‡abd Aniruddha Sengupta,‡abd Swadhin K. Mandal,‡c
Monideepa Roy‡*abd and Shiladitya Sengupta‡*abef
Despite the advances in the design of antibody–drug conjugates (ADCs), the search is still ongoing for novel
approaches that lead to increased stability and homogeneity of the ADCs. We report, for the ﬁrst time, an
ADC platform technology using a platinum(II)-based linker that can re-bridge the inter-chain cysteines in
the antibody, post-reduction. The strong platinum–sulfur interaction improves the stability of the ADC
when compared with a standard maleimide-linked ADC thereby reducing the linker–drug exchange with
albumin signiﬁcantly. Moreover, due to the precise conserved locations of cysteines, both homogeneity
and site-speciﬁcity are simultaneously achieved. Additionally, we demonstrate that our ADCs exhibit
increased anticancer eﬃcacy in vitro and in vivo. The Pt-based ADCs can emerge as a simple and
exciting proposition to address the limitations of the current ADC linker technologies.
Introduction
Antibody–drug conjugates (ADCs) have emerged as a new genre
of cancer therapeutics that involves the antibody-mediated
delivery of highly potent cytotoxic agents specically to the
cancer cells expressing the target antigen. With more than
50 ADCs currently in the clinical pipeline,1 the prospects for the
ADC eld have escalated remarkably since the approvals of
brentuximab vedotin (Adcetris™)2 for Hodgkin’s lymphoma in
2011 and ado-trastuzumab emtansine (Kadcyla™)3 for HER2+
breast cancer in 2013.
The success of an ADC is dependent on various factors such as
the target antigen, the antibody and the drug. However, the
mainstay of an eﬀective ADC lies in its linker—the glue that
couples the drug and the antibody together until the ADC reaches
the cancer cell. Conventionally, linker–drugs have been coupled
to either lysines on the antibody, as in ado-trastuzumab emtan-
sine,3 or to cysteines viamaleimide chemistry, as in brentuximab
vedotin (Scheme 1a and b).2 Both technologies have major limi-
tations, such as the former producing heterogeneous ADCs4,5 and
Scheme 1 Comparison of conventional linker technologies with
a Pt(II)-linker. (a) Conjugation to lysines results in a heterogeneous
mixture. (b) Conjugation to cysteines via maleimide leads to reduced
higher order structural stability and instability in the presence of
albumin. (c) Pt(II)-linker re-bridges the antibody chains with strong
Pt–S interaction imparting stability, homogeneity and site-speciﬁcity.
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the latter being unstable during circulation.6 While heteroge-
neous ADCs have unpredictable safety and PK proles and show
batch-to-batch variability, the instability of maleimide chemistry
results in oﬀ-target toxicity.4 These shortcomings with current
linker technologies have hindered the concept of an ideal “magic
bullet”, as envisioned by Paul Ehrlich,7 to be realized.
In the last few years, several ideas have emerged to address
these issues.8 The use of unnatural amino acids,9 additional
cysteines10 and transglutaminase11 for site-specic conjugation
have shown promise in reducing the heterogeneity of ADCs but
require genetic engineering and involve complex processes.
Furthermore, these methods pose challenges during the
manufacturing and scale-up processes. Attempts to stabilize the
maleimides by accelerating the thiosuccinimide ring hydrolysis
have been shown to result in more eﬃcacious and relatively
safer ADCs.12 Alternative strategies to maleimide-based conju-
gations have also surfaced where the disuldes are re-bridged
aer cysteine reduction.4 Despite the potential advantages of
these technologies, they all employ the C–S bond for conjuga-
tion, which is known to undergo a retro-Michael reaction
resulting in the exchange of the linker–drug with thiol-con-
taining molecules such as albumin.4 This not only leads to
premature loss of ADC molecules from circulation but also
causes toxic side eﬀects.12 There is an imperative need to
improve upon the conventional linker technologies with a goal
to enhance their stability, site-specicity and ability to produce
homogeneous ADCs in a facile manner.
Overcoming the current challenges with ADC linker tech-
nologies requires meticulous thought into the design aspects of
the linker–drug, particularly, the strength of the antibody–
linker bond. It is known that platinum(II) ions can form strong
edge-sharing binuclear Pt(d8) complexes with sulfur bridges
while reacting with thiols at a physiological pH.13–16 We report
a novel technology employing Pt(II) as a linker that is able to re-
bridge the antibody chains aer conjugation (Scheme 1c). We
rationalized that the Pt(II) mediated binding with the antibody
should render the required stability to the ADC during circu-
lation thereby improving upon the conventional maleimide
chemistry. Using cetuximab, an antibody that inhibits the
epidermal growth factor receptor (EGFR), trastuzumab, which
blocks the human epidermal growth factor receptor 2 (HER2),
and rituximab, which binds to CD20, as the antibodies and
camptothecin (CPT) as a ‘proof of concept’ payload, here we
report the engineering of novel Pt(II)-based prototype ADCs. The
Pt-based ADCs exhibit superior stability when compared to
maleimide-based ADCs, as well as being potent in antigen +ve
cells and eﬃcacious in vivo in a lung adenocarcinoma xenogra
model. The Pt(II) linker technology has the potential to
surmount the bottlenecks of instability and heterogeneity with
the existing linker technologies.
Results
Pt(II)-linker–drug design
We rationalized that the high aﬃnity of platinum for sulfur
could lead to a superior stability of the Pt-linker-based ADC.
This strong aﬃnity is due to so–so interaction between the
Pt(II) and sulde ions as per the well-known hard–so acids
and bases (HSAB) principle. The bond energy of a Pt–S bond
(114 kcal mol1)17 is signicantly higher than that of a C–S bond
(70–80 kcal mol1)18 present in the case of maleimide linkers
or existing re-bridging technologies.4 Keeping this strong Pt–S
interaction in mind, we designed and synthesized a Pt-based
linker–drug (Pt–PEG–CPT) (Scheme 2, see ESI† for details), that
takes advantage of the two labile Pt–Cl bonds which can be
easily cleaved to form Pt–S bonds on treatment with a reduced
antibody in aqueous medium.
We used camptothecin (CPT), an easily available topoisom-
erase-I inhibitor with nanomolar range potency, as the ‘proof of
concept’ payload for this study. Additionally, camptothecin has
a characteristic UV spectrum and uoresces when excited at
369 nm, which facilitates downstream analytical characteriza-
tion. Since CPT is a hydrophobic drug with poor solubility in an
aqueous environment, ADCs with CPT are expected to be
hydrophobic and could result in immunogenic aggregates4 that
can undergo rapid plasma clearance.19 To overcome this issue,
a hydrophilic polyethyleneglycol (PEG) unit was incorporated by
coupling to the hydroxyl group of CPT via an ester bond
Scheme 2 Structure, design and synthesis of Pt–PEG–CPT. (Reagents
and all intermediates are shown in the ESI;† PEG: polyethyleneglycol.)
2388 | Chem. Sci., 2017, 8, 2387–2395 This journal is © The Royal Society of Chemistry 2017
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(Scheme 2). It should be noted that such a construct can impart
stability to the CPT molecule during circulation,20 and the ester
bond can be easily cleaved by esterases present in the tumour
cellular environment, thereby releasing the active camptothecin
moiety from the linker.21 The platinum(II) ion was incorporated
by the reaction between PEG–CPT and the amine ligand,
resulting in the formation of a Pt–PEG–CPT molecule with two
labile Pt–Cl bonds that would enable Pt–S bridge formation in
the presence of thiol groups. The molecule was HPLC puried
and has been characterized by 1H, 13C and 195Pt NMR, IR
spectroscopy and mass spectrometry (see ESI†). A single and
sharp signal at 2977 ppm in the195Pt NMR spectrum estab-
lished diamino dichloro platinum coordination.22 In order to
compare our Pt-based technology with state-of-the-art mal-
eimide chemistry, a similar linker–drug, mal–PEG–CPT,
replacing the Pt(II) with 6-maleimidocaproic acid, was also
synthesized and fully characterized (see ESI†).
Preparation and characterization of the ADCs
ADCs are designed using antibodies against well-known anti-
gens that are over-expressed on cancer cells compared to
normal cells. The antibody is selected for high specicity and
aﬃnity towards the antigen, which can minimize the oﬀ-target
eﬀects. Three such antibodies, cetuximab (Ctx), trastuzumab
(Tra) and rituximab (Rtx), which target EGFR, HER2 and CD20
respectively, are ideal candidates fullling both criteria and
were therefore used in this study to prove the concept. Conju-
gation was performed by reducing the antibodies in the pres-
ence of an excess amount of tris(2-carboxyethyl)phosphine
(TCEP) to expose all the 8 inter-chain thiols and incubating
them with excess Pt–PEG–CPT or mal–PEG–CPT. Purication by
buﬀer-exchange ensured the removal of any unbound linker–
drug. Furthermore, the conjugation to the antibody was
conrmed by the inherent uorescence of CPT as monitored
inline via size-exclusion HPLC (SE-HPLC). The SE-HPLC result
of Ctx–Pt–PEG–CPT suggests the conjugation of the linker–drug
to cetuximab as observed by the characteristic uorescence of
CPT corresponding to the antibody peak (Fig. 1a and b). The
conjugates were highly pure with less than 1% aggregates
(measured by absorbance at 280 nm) and less than 1% free
linker–drug in the ADC (measured by absorbance at 369 nm).
Similarly, conjugates were also prepared with trastuzumab
(Tra–Pt–PEG–CPT) and rituximab (Rtx–Pt–PEG–CPT) which
demonstrated good purity by SE-HPLC (Fig. 1c and d; ESI
Fig. S1†).
The quantication of the bound CPT concentration was
carried out by UV spectroscopy whereas the concentration of Pt
was assessed by atomic absorption spectroscopy (AAS). Drug-to-
antibody ratios (DARs) were calculated by measuring the
absorbance of ADC at 254 nm and 280 nm and the extinction
coeﬃcients of the respective linker–drug and the antibody at
both wavelengths.23 The concentration of Pt corroborates well
with the CPT concentration which demonstrates the presence of
the two species in the ADC in a 1 : 1 molar ratio. As an example,
for one batch of Tra–Pt–PEG–CPT, the CPT concentration by UV
spectrometry was measured as 164 mM while the Pt-concentra-
tion by AAS was determined to be 161 mM. The addition of
an excess of Pt–PEG–CPT resulted in a maximum DAR of
8 with all three antibodies. Since there are 4 disulde bonds
per antibody, this implies a stoichiometry of 2 Pt–PEG–CPT
molecules per disulde bridge as anticipated. Similarly, with
mal–PEG–CPT, an addition of excess linker–drug results in
a maximum DAR of 8 with a stoichiometry of 1 mal–PEG–CPT
per reduced cysteine. Previously it had been suggested that
the optimal DAR is 4 for in vivo studies as higher DAR ADCs
result in altered pharmacokinetics due to their hydrophobic
nature.23 The conjugation reaction, thus, was stoichiometrically
controlled to ensure DARs of 2.5–4.
The Pt(II)-linker was designed to bind to the exposed thiols of
the reduced antibody. However, since it is known that Pt(II) can
also bind to various amino acids such as histidine, methionine,
cysteine etc.,24,25 we conrmed that our Pt–PEG–CPT molecule
binds only to the reduced antibody upon exposure of cysteine
thiols i.e., Pt–PEG–CPT showed negligible association (DAR:
0.26) with the non-reduced antibody, thus corroborating our
design.
A concern with any ADC is the potential conformational
change due to the conjugation of hydrophobic drugs which
results in an altered antigen binding ability. To understand the
impact of Pt-based conjugation on the protein conformation, an
ELISA was performed by capturing antibodies and their
respective ADCs using their target (Fig. 2). The aﬃnity constant
(Kd) was found to be similar for both the antibody and the ADC
and comparable to the reported Kd values,26–28 suggesting that
the conformational change, if any, is local and does not impact
the antigen-binding domains of the antibody.
Preparation of Fab–drug conjugate and heterogeneity
Heterogeneity is a vital parameter for any ADC technology as
variations in the site of attachment lead to batch-to-batch
disparities, resulting in inconsistent eﬃcacy and safety
proles.6 ADCs prepared through conventional linker technol-
ogies result in a heterogeneous product with multiple species.
To understand the heterogeneity of ADCs made with the Pt(II)
Fig. 1 SE-HPLC proﬁles of conjugates. Chromatogram of Ctx–Pt–
PEG–CPT (a) at 280 nm showing low presence of aggregates (<1%)
and (b) ﬂuorescence of CPT corresponding to the antibody peak with
negligible presence of free camptothecin (<1%). Chromatogram of
Tra–Pt–PEG–CPT (c) at 280 nm showing low presence of aggregates
(2%) and (d) ﬂuorescence of CPT corresponding to the antibody peak
with negligible presence of free camptothecin (<1%).
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 2387–2395 | 2389
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linker, a trastuzumab-Fab fragment (TraFab) was prepared
and conjugated to Pt–PEG–CPT and mal–PEG–CPT. As the
Fab arm contains only one inter-chain disulde, the analysis of
the resulting Fab–drug conjugate (TraFab–Pt–PEG–CPT or
TraFab–mal–PEG–CPT) was simplied. With excess linker–drug,
the maximum achievable DAR, as measured by UV spectroscopy,
was 1.9 for TraFab–Pt–PEG–CPT validating that two Pt–PEG–CPT
molecules bind to each disulde. With TraFab–mal–PEG–CPT,
the maximum achievable DAR was 1.7.
The Fab–drug conjugates were assayed by analytical hydro-
phobic interaction chromatography (HIC). TraFab–Pt–PEG–CPT
(DAR: 1.9 by UV) showed two conjugated species (Fig. 3a). Both
of the peaks were successfully separated by HIC (Fig. 3b) and
were found to have a DAR of2 by UV spectroscopy. The DAR by
HIC was calculated to be 1.9 and the eﬃciency of the conjuga-
tion was 95%. Similarly, TraFab–mal–PEG–CPT (DAR: 0.65 by
UV) showed two conjugated species (Fig. 3c) which were sepa-
rated by HIC. The DAR by HIC was calculated to be 0.59.
However, the peak at 24 min (Fig. 3c, peak 4) had a DAR of 1
whereas the peak at 30 min (Fig. 3c, peak 5) had a DAR of 2.
These results imply that the Pt(II) linker yields more homoge-
neous ADCs with predominantly bi-conjugated ADC species
compared to a heterogeneous mixture obtained with the mal-
eimide linker. Therefore, the eﬀective concentration of active
molecules is enriched in the mixture, avoiding the need for
further downstream purication procedures, thus ensuring an
economical process.
Stability of the ADCs
One of the critical features that contributes to the design of
a successful ADC is a linker that is stable during circulation,
yet able to specically release the payload eﬃciently at the
target site. It is known that maleimide-based ADCs tend to
exchange the linker–drug with the free thiol present on
albumin, resulting in oﬀ-target eﬀects and a depletion of ADC
levels in vivo.29 This instability is due to a retro-Michael reac-
tion that regenerates the reactive maleimide (Scheme 3a). To
investigate the stability of the ADCs in the presence of human
serum albumin (HSA), both cetuximab ADCs, Ctx–Pt–PEG–CPT
and Ctx–mal–PEG–CPT, and both trastuzumab ADCs, Tra–Pt–
PEG–CPT and Tra–mal–PEG–CPT, were incubated in the pres-
ence of HSA. Albumin was puried and the sample was assayed
by SE-HPLC with inline uorescence monitoring. As campto-
thecin is known to non-covalently bind to albumin,30 iso-
propanol was used in the mobile phase for dissociating loosely
bound CPT from albumin which eluted aer 8 min on the SEC
column. Albumin showed a retention time of 6.4 min on the
SEC column with inherent uorescence which was subtracted
as background during calculations (ESI† Fig. S2). Aer 72 h of
incubation, the uorescence peak intensity of albumin was
signicantly higher in the case of the maleimide-based ADC as
compared to the Pt-based ADC (Fig. 4). Our ndings in the
present study demonstrated that there was at least a 4-fold
higher linker–drug exchange to albumin with the maleimide-
based ADC than with the Pt-based ADC, hence validating the
superior stability of the Pt(II) linker technology (Scheme 3b).
The conventionally used maleimide linkers reduce the struc-
tural stability of the antibody due to the absence of covalent
inter-chain bonds.29 This results in the separation of the heavy
Fig. 2 Antigen-binding ability. ELISA demonstrating that the aﬃnity of
the antibody is not compromised upon Pt(II)-based conjugation. (a) Ctx
and Ctx–Pt–PEG–CPT binding to EGFR. (b) Tra and Tra–Pt–PEG–CPT
binding to HER2. (c) Rtx and Rtx–Pt–PEG–CPT binding to CD20. (d)
Calculated Kd values compared with reported binding aﬃnities.26–28
Error bars represent standard error of the mean.
Fig. 3 HIC proﬁles of TraFab–drug conjugates. (a) A representative HIC
proﬁle at 280 nm of TraFab–Pt–PEG–CPT (DAR: 1.9 by UV), demon-
strating > 95% conjugation eﬃciency and homogeneity. The DAR was
calculated to be 1.9 by HIC. (b) A representative HIC proﬁle at 280 nm
of the puriﬁed peak of TraFab–Pt–PEG–CPT (27.8 min). The DAR was
veriﬁed by UV spectroscopy as 2. (c) A representative HIC proﬁle at
280 nm of TraFab–mal–PEG–CPT (DAR: 0.65 by UV) demonstrating
heterogeneity with the presence of both DAR1 and DAR2 species. The
DAR was calculated to be 0.59 by HIC. (1) Unconjugated Fab; (2)
TraFab–Pt–PEG–CPT (DAR: 2); (3) TraFab–Pt–PEG–CPT (DAR: 2); (4)
TraFab–mal–PEG–CPT (DAR: 1); (5) TraFab–mal–PEG–CPT (DAR: 2).
2390 | Chem. Sci., 2017, 8, 2387–2395 This journal is © The Royal Society of Chemistry 2017
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chain from the light chain of the antibody when analyzed on
a denaturing SDS-PAGE gel. However, with the Pt(II) linker, we
observe that the heavy chain and light chain of all the ADCs,
whether with the whole antibody or with the Fab fragment, do
not separate on the gel and the majority of the ADC appears as
a single band corresponding to the intact molecular weight
(Fig. 5; Lane 3 vs. Lane 4). The bands in the ADC lanes (Fig. 5;
Lane 3 and Lane 4) show uorescence when the gel is viewed
under UV light, ensuring that the CPT remains conjugated to the
antibody on the gel. This data suggests the presence of strong
interactions between the antibody chains in Pt(II)–ADC unlike in
maleimide–ADC thereby preserving the higher order structural
stability.
Encouraged by the stability of the Pt-based ADC in the
presence of albumin and its conserved higher order structure,
we next assessed its stability in the presence of human and
mouse plasma. Instability of the linker technology during
circulation in the blood stream would result in the premature
release of the drug, leading to dose-limiting side eﬀects. Ctx–Pt–
PEG–CPT and Tra–Pt–PEG–CPT were incubated in human and
mouse plasma at 37 C and samples were withdrawn at various
time-points. Extracted camptothecin species from the samples
were analyzed by reverse-phase HPLC (RP-HPLC) using a uo-
rescence detector and the platinum content in the samples was
measured by Pt–AAS. The stability of Ctx–Pt–PEG–CPT and
Tra–Pt–PEG–CPT in human plasma was demonstrated by an
extended half-life of 94 h and 133 h, respectively, in vitro (Fig. 6a
and c) which is a signicant improvement when compared with
IMMU-132, a maleimide-based ADC with SN-38 (camptothecin
derivative) in clinical trials, having a half-life of only 24 h in
human serum.31 Inmouse plasma, the half-lives were 12.4 h and
9.01 h for Ctx–Pt–PEG–CPT and Tra–Pt–PEG–CPT respectively
(Fig. 6b and c). The lower half-life in mouse plasma is expected
due to the presence of elevated levels of esterase.32 In one report,
for an ADC, a 70-fold lower half-life of only 4 h was observed in
mouse plasma than in human plasma.33 It is also interesting to
note that only CPT and not Pt–PEG–CPT was detectable by
HPLC in all samples and no platinum was detected in any of the
samples by Pt-AAS, which suggests that Pt–PEG–CPT does not
release from the ADC and the cleavage is at the ester bond only.
This further establishes that the Pt-based ADC can resist even
the harsh environment of the plasma.
Biological characterization of the ADCs
The goal of any ADC is to combine the specicity of the
antibody with the potency of the drug which was elucidated
by in vitro cytotoxicity assays in EGFR or HER2-amplied cell
Scheme 3 ADC stability in the presence of albumin. (a) Maleimide
linkers undergo a retro-Michael reaction regenerating the maleimide
which can react with the free thiol present on albumin. (b) Pt(II)-linker is
signiﬁcantly less reactive towards the albumin thiol.
Fig. 4 Stability in the presence of albumin. An overlay of the SE-HPLC
ﬂuorescence chromatogram of the albumin fraction post-incubation
with (a) Ctx–Pt–PEG–CPT, (b) Ctx–mal–PEG–CPT, (c) Tra–Pt–PEG–CPT
and (d) Tra–mal–PEG–CPT at 0 h and 72 h demonstrates that at least
4-fold more linker–drug attaches to albumin covalently in the case of
mal–PEG–CPT when compared with Pt–PEG–CPT. (*): albumin peak;
the peaks eluting post 8 min are unconjugated free low molecular
weight species.
Fig. 5 Higher-order structural stability. SDS-PAGE gel (Coomassie-
stained) under non-reducing conditions, showing that the antibody
light chain and heavy chain are held together by strong forces via the
Pt(II) linker. Fluorescence corresponding to CPT can be visualized on
the gel under UV light. (a) Cetuximab, (b) trastuzumab, (c) rituximab, (d)
trastuzumab Fab and (e) cetuximab Fab.
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 2387–2395 | 2391
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lines with Ctx–Pt–PEG–CPT and Tra–Pt–PEG–CPT respec-
tively. The non-targeted eﬀects of conjugates were assessed
on cell lines expressing low levels of antigen. Our ndings
revealed that the conjugates of Pt–PEG–CPT with both
cetuximab and trastuzumab, have demonstrated excellent
specicity and potency in vitro. Ctx–Pt–PEG–CPT treatment
resulted in a 118-fold lower IC50 in MDA-MB-468 (EGFR high)
as compared to in MCF-7 (EGFR low) (Fig. 7a) while Tra–Pt–
PEG–CPT showed a 327-fold lower IC50 in SK-BR-3 (HER2
high) than in MDA-MB-453 (HER2 low) (Fig. 7b). We evalu-
ated the potency in several other cell lines which showed
similar trends (Fig. 7c). These results indicate the specicity
of the present ADCs towards the target cells and that the
payload is released from the linker upon internalization in
the active form.
We next tested the specicity and potency of the Pt-based
ADC in vivo in a A549 non-small cell lung cancer (NSCLC) model
wherein a tumour growth inhibition (TGI) of 55% was achieved
as compared to the control (Fig. 8a). Up to 10 doses of
20 mg kg1 Ctx–Pt–PEG–CPT could be administered without
any loss in body weight (Fig. 8b), suggesting a higher thera-
peutic window of the ADC. A TUNEL assay demonstrated that
the tumour sections from ADC-treated mice had 80%
apoptotic cells, while sections from those treated with cetux-
imab had only 20% apoptotic cells (Fig. 8c and d).
Discussion
ADCs hold the promise of revolutionizing cancer treatment by
increasing antitumour eﬃcacy while overcoming the collateral
damage associated with conventional chemotherapeutic drugs
via targeted delivery. Although the approvals of ado-trastuzu-
mab emtansine and brentuximab vedotin in this decade have
set the tone for the future of ADCs,1 adverse eﬀects are known to
occur before the optimal therapeutic dose is reached with these
drugs, hence limiting their clinical outcome. In order to widen
the therapeutic window, strategies involving target selection,
innovative linker technologies and payload potency need to
Fig. 6 Plasma stability. The stability of Ctx–Pt–PEG–CPT and Tra–Pt–
PEG–CPT in (a) human plasma and (b) mouse plasma demonstrates
the superior stability of the Pt-based conjugation with extended half-
lives (c).
Fig. 7 In vitro potency of ADCs. Cell viability was assessed using an
MTT assay and IC50 values were calculated. (a) The Ctx–Pt–PEG–CPT
conjugate showed a 118-fold increase in anti-proliferative activity on
EGFR-high cells (MDA-MB-468) as compared to EGFR-low cells
(MCF7). (b) The Tra–Pt–PEG–CPT conjugate showed a 327-fold
increase in anti-proliferative activity on HER2-high cells (SK-BR-3) as
compared to on HER2-low (MDA-MB-453) cells. Error bars represent
standard error of the mean for at least 3 independent experiments. (c)
IC50 values (drug-equivalent concentration of ADC) obtained for
various cell lines demonstrate the speciﬁcity and potency of the ADCs.
Standard errors reported from at least 3 independent experiments.
*Extrapolated values.
Fig. 8 In vivo eﬃcacy. Antitumour activity of Ctx–Pt–PEG–CPT was
evaluated in an A549 xenograft model in SCID Beige mice. The mice
were implanted with 5  106 A549 cells and grouped as untreated
(control), cetuximab (Ctx) or Ctx–Pt–PEG–CPT (ADC) on a dosing
schedule of q4dx5 for 2 cycles at 20 mg kg1 of test article. (a) The
Ctx–Pt–PEG–CPT treated animals showed signiﬁcant diﬀerences in
tumour volume compared with the control group (P < 0.016), with
a tumour growth inhibition (TGI) of 55%. (b) No signiﬁcant diﬀerence in
body weight was observed across the groups. (c) Tumour sections
examined using a TUNEL assay (TUNEL, TMR-Red; Hoechst, blue)
show a higher number of apoptotic cells in ADC treated tumours.
Scale bar, 20 mm. (d) The percentage of TUNEL-positive cells in ADC
treated tumour sections is signiﬁcantly higher than those observed for
cetuximab treated samples. **p < 0.0001; *p < 0.005.
2392 | Chem. Sci., 2017, 8, 2387–2395 This journal is © The Royal Society of Chemistry 2017
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evolve to design the ideal “magic bullet”. Here we report a novel
Pt(II) based linker that re-bridges the antibody chains post
reduction and provides a facile alternative to address the key
issues of ADC linkers. The presence of strong interactions
between the antibody chains in the Pt-based ADC preserves the
higher order structural stability when compared to the mal-
eimide-based ADC, in which non-covalent forces exist as eluci-
dated with three diﬀerent antibodies. The labile C–S bond in the
case of maleimide, is overcome by the strength of the Pt–S
interaction imparting the necessary stability to the ADC. Addi-
tionally, for any IgG1, the location of inter-chain cysteines is
conserved and hence, the attachment of the linker–drug is site-
specic and the high eﬃciency of the Pt–S reaction ensures that
the resulting ADC is homogeneous.
While the premature release of the linker–drug from the
antibody would result in oﬀ-target eﬀects, a very stable linker
would be non-eﬃcacious. Thus, careful selection and subse-
quent optimization of the payload and linker–payload combi-
nation is required to generate ADCs with maximal therapeutic
eﬃcacy. Another crucial factor for achieving success at the clinic
is the requirement for the production of homogeneous ADCs,
which may even become a prerequisite for future FDA
approvals. However, ADCs prepared through conventional
linker technologies, such as conjugation to lysines of the anti-
body, exhibit heterogeneity with multiple species, which is
addressed by the Pt-based re-bridging of the disuldes on
dened cysteines. On the other hand, conjugation to cysteines
via maleimides can lead to the exchange of the linker with the
free thiol present on albumin, thus resulting in oﬀ-target eﬀects
and a depletion of ADC levels in vivo. Since albumin is the most
abundant protein in plasma and is ubiquitously taken up by all
cells, this poses a signicant challenge, especially when pico-
molar potency drugs are employed. Interestingly, our ndings
in the present study demonstrate that in comparison to the
Pt-linker, at least four times more linker–drug exchange to
albumin occurs in the case of the maleimide-linked ADC,
indicating that the Pt(II) linker technology could lead to more of
the intact ADC being available for delivery to cancer cells in vivo.
The increased stability is consistent with the high aﬃnity that
platinum has for sulfur. It is well known that in the case of
chemotherapeutic platinum drugs, such as cisplatin, a major
fraction of the administered drug binds to sulfur-containing
molecules such as glutathione, albumin, methionine etc., and is
unavailable to reach and bind to its target (DNA).13 Indeed,
sulfur-containing molecules, such as WR-2721, are used as
chemoprotectants for Pt–drugs due to their ability to quench
excess drug and alleviate toxicity.13 The Pt-linked conjugate
described here already employs a strong Pt–S interaction
thereby preventing competition from other sulfur-containing
molecules and providing it extra stability during circulation.
Additionally, the potency of the ADC in the in vitro studies,
together with the in vivo eﬃcacy, implies that the chemothera-
peutic drug is optimally released within the cell. Taken
together, our results indicate that the Pt-based ADC platform
meets the requirement of stability in addition to homogeneity.
The stability of the linker coupled with the choice of payload
is instrumental in determining the therapeutic window.34,35 The
initial development with ADCs used nanomolar range cytotoxics
such as doxorubicin, which did not succeed in translating to
clinical development. It was speculated that the low potency of
the drug was responsible for the lack of eﬃcacy. It was later
discovered that the main reason for its failure was the choice of
the antigen rather than the cytotoxic itself.36,37 The current trend
with ADCs is to employ drugs eﬀective in a sub-nanomolar
range such as calicheamicins, maytansinoids and auristatins.1
However, using such highly potent cytotoxics implies that even
small amounts of the drug leaching out from the ADC can result
in signicant oﬀ-target toxicity, as was observed in Mylotarg™,
an ADC that employs a low-stability pH-sensitive linker with
calicheamicin as the payload, which was withdrawn from the
market due to toxicity issues.34 With a better choice of antigens
and antibodies and the optimization of the linker technology, it
has been realized that drugs with nanomolar potency, such as
camptothecin, could also prove eﬃcacious. In fact, ADCs
employing SN-38, a camptothecin derivative, are in phase 1/2 of
clinical development1 and oﬀer the advantage of a wider ther-
apeutic window.37 Indeed, we observed that we could admin-
ister 10 doses of our ADC at 20 mg kg1 without any visible
adverse eﬀects, potentially arising from the enhanced stability
of the Pt–S interaction and the use of a nanomolar potency drug
in camptothecin.
It has been reported that an ADC with a DAR of 8 is less
eﬀective in vivo than one with a DAR of 4,23 which has led to the
norm of targeting a DAR of 4 for an ADC. However, recent
ndings suggest that by reducing the hydrophobicity of the
ADC, the ADC with a DAR of 8 performs much better in vivo19
and is a feasible alternative. Thus, the higher DAR would not be
a disadvantage if the linker was made hydrophilic by the use of
PEG, for example, to alter the pharmacokinetic properties. For
instance, the Fleximer technology conjugates up to 20 drug
molecules per antibody without concerns due to the presence of
a very hydrophilic polymer.38 With the Pt(II) linker, as it is
possible to achieve a maximum DAR of 8, we included a PEG
chain in our linker-design to compensate for the drug's hydro-
phobicity, which decreased aggregation of the resulting ADCs. If
more hydrophobic drugs were to be employed or higher DARs
were desired, higher chain length of PEG could be built-in to the
design. Pt(II)-linked ADCs thus allow the exibility of higher
loading of drug per antibody resulting in an enhanced delivery
of the payload. Overall, higher-DAR ADCs coupled with a stable
linker like Pt(II) and a nanomolar potency drug such as camp-
tothecin would provide a wider therapeutic window, and can
potentially circumvent the use of extremely potent cytotoxics
that are associated with dose-limiting toxicities in the clinic.
Conclusions
In summary, we have envisioned a novel platform technology
using Pt(II) as a linker, which can be applied to generate stable
ADCs that are eﬀective in vitro as well as in vivo with a broad
range of antibodies. Pt(II) provides a facile avenue to not only
conjugate drugs to an antibody but also could be easily
extended to the broad spectrum of bioconjugation processes in
general. Most biomolecules possess amenable groups such as
This journal is © The Royal Society of Chemistry 2017 Chem. Sci., 2017, 8, 2387–2395 | 2393
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the thiols of the cysteines that would have strong interaction
with Pt(II), thereby allowing for stable coupling products. The
Pt–S interaction as employed here would add to the repertoire of
robust linkers available for designing novel and eﬃcient cancer
therapeutics.
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